Last reviewed · How we verify
NCT04109235: FHT HIIT
Family Health Team High-Intensity Interval Training
NA trial testing High-Intensity Interval Training Physical Activity (PA) Advice in Type 2 Diabetes in 20 participants. Currently enrolling.
13 July 2026
Quick facts
| Lead sponsor | Western University, Canada |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 13 February 2020 |
| Primary completion | 13 July 2026 |
| Estimated completion | 13 July 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- High-Intensity Interval Training Physical Activity (PA) Advice
- Population-Based Physical Activity (PA) Advice
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Western University, Canada
Who can join
18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the rapid shift to virtual care, this pilot study aims to determine the feasibility of prescribing low-duration, interval-based training through virtual care. If successful, this study will inform a larger randomized control trial to determine if the prescription of low-duration interval-based training improves chronic disease through the measurement of hemoglobin A1C (HbA1C), and weight to a greater extent than the general guideline to aim for 150 minutes of PA weekly.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04109235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Western University, Canada trials
Trials by the same sponsor.
- NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
- NCT07372755 — Feasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders · not yet recruiting
- NCT07302308 — Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders. · not yet recruiting
- NCT04323423 — The DURATION Study: reDUcing sedentaRy behAviour to Maintain cogniTIve functiON. · NA · withdrawn
- NCT07204301 — Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Pat · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04109235 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Western University, Canada
- Last refreshed: 12 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04109235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing